| Net sales | 524.19K |
| Cost of sales | 706.02K |
| Gross profit (loss) | -181.82K |
| Selling, general and administrative | 1.19M |
| Impairment loss | |
| Research and development | |
| Total operating expenses | |
| Operating loss | -1.37M |
| Interest and financing costs | -223.61K |
| Interest income | 33.25K |
| Other, net | 105.51K |
| Other expense, net | -78.96K |
| Loss from continuing operations before income taxes | |
| Income tax benefit | |
| Loss from continuing operations | |
| Gain on sale of discontinued operations, net of taxes | |
| Income from discontinued operations, net of taxes | |
| Total Discontinued operations | |
| Net loss | |
| Unrealized income on marketable investments | |
| Comprehensive loss | |
| Loss from continuing operations per share - basic and diluted (in dollars per share) | -0.02 |
| Income from discontinued operations per share - basic and diluted (in dollars per share) | |
| Net loss per share - basic and diluted (in dollars per share) | -0.03 |
| Weighted average shares outstanding - basic (in shares) | 60.13M |
| Weighted average shares outstanding - diluted (in shares) | 60.13M |